New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 17, 2014
05:52 EDTREGNRegeneron upgraded to Buy from Neutral at Citigroup
Citigroup upgraded it rating on Regeneron (REGN) to Buy from Neutral after its survey of retinal surgeons indicated the company's Eylea drug will beat estimates over the near and long term. Citi also believes Regeneron's pipeline is not adequately reflected in the current share price. The firm raised its price target for the stock to $390 from $342. Shares of Regeneron closed Friday up $1.43 to $329.50.
News For REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
14:04 EDTREGNRegeneron price target raised to $500 from $450 at Argus
Subscribe for More Information
March 25, 2015
11:03 EDTREGNRegeneron confirms FDA approval of EYLEA
Subscribe for More Information
10:35 EDTREGNFDA approves expanded indication for Eylea
Subscribe for More Information
March 23, 2015
07:17 EDTREGNAmerican Academy of Dermatology to hold annual meeting
73rd Annual Meeting of AAD is being held in San Francisco on March 20-24.
March 20, 2015
10:00 EDTREGNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:05 EDTREGNRegeneron initiated with a Buy at Chardan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use